Company News

Share this article:

Abbott will acquire the Solvay Group, including the pharmaceutical and vaccine business, for $6.6 billion in cash, the company announced. Abbott expects Solvay Pharmaceuticals, based in Belgium, to bring in an additional $3 billion in annual sales, and extend the company's reach in emerging global markets.

Merck announced an exclusive agreement with CSL Biotherapies to market and distribute Afluria, a flu vaccine. The six-year deal extends through flu season of 2016. Financial terms of the deal were not disclosed. Merck also pays royalties to CSL for its intellectual property patent on Gardasil, Merck's HPV vaccine.  

Johnson & Johnson announced a collaboration with Netherlands-based Crucell for the development of monoclonal antibodies and vaccines for the flu and other diseases. The partnership unites J&J subsidiary Ortho-McNeil-Janssen Pharmaceuticals with Crucell, in a $442 million deal that buys J&J an 18% ownership stake in Crucell. The partnership will immediately focus on the development and commercialization of a flu vaccine, according to a statement.


Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Imbruvica lassoes CLL indication

The FDA slapped a Breakthrough Therapy label on the CLL indication pursuit in February.

FDA asks social media "how'm I doin?"

The FDA's Center for Drug Evaluation and Research's Office of Communications wants a system that will help assess its messaging reach across the interwebs and its many forums.

Reckitt Benckiser wants out of pharma

The company plans to spin off its pharmaceutical unit.